Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Benlysta Market Growth Potential: How Will Market Size Shift Through 2030?
The benlysta market has undergone rapid expansion in recent years. It is forecast to grow from $2404.67 million in 2025 to $2677.94 million in 2026, at a compound annual growth rate (CAGR) of 11.4%. The surge observed in the historic period can be attributed to limited effective sle therapies, biologic drug innovation, early belimumab approvals, specialist rheumatology adoption, and unmet autoimmune treatment needs.
The benlysta market size is expected to experience substantial growth over the next few years, projected to reach $4073.18 million in 2030, driven by a compound annual growth rate (CAGR) of 11.1%. This anticipated expansion during the forecast period is attributed to factors such as rising lupus diagnosis rates, the addition of new indications like lupus nephritis, improved access to biologic treatments, strengthened reimbursement support, and heightened specialist awareness. Significant trends for the forecast period include the increasing adoption of targeted autoimmune therapies, the broader expansion of biologic treatments within lupus care, a discernible shift towards long-term disease-modifying agents, a growing preference for subcutaneous administration, and an increased focus on preventing organ damage.
Get A Free Sample Report With In-Depth Market Insights:
Benlysta Market Growth Factors Behind Sustained Expansion
The escalating number of new autoimmune disease cases is projected to propel the Benlysta market forward. Autoimmune diseases are a group of conditions where the body’s immune system mistakenly attacks its own healthy cells, tissues, and organs. The increasing prevalence of these diseases is attributed to factors such as enhanced diagnosis, environmental triggers, lifestyle changes, genetic predisposition, and an aging population. Benlysta aids in managing autoimmune diseases, particularly systemic lupus erythematosus (SLE), by targeting and inhibiting the B-lymphocyte stimulator (BLyS) protein. This protein plays a crucial role in the overactive immune response, thereby reducing the survival of harmful B cells, preventing them from attacking healthy tissues, and ultimately helping to control disease activity, minimize flare-ups, and improve patient outcomes. For instance, in March 2024, the National Health Council, a US-based nonprofit organization, reported that approximately 50 million people in the United States are impacted by autoimmune diseases, although this figure might underestimate the true prevalence due to diagnostic challenges. Worryingly, autoimmunity is on the rise, with some studies indicating an annual increase ranging from 3% to 12%. Furthermore, in February 2024, according to the National Library of Medicine, a US-based biomedical library, the global incidence of autoimmune diseases rises by 19.1% annually, while their prevalence increases by 12.5% each year. Consequently, the surge in new cases of autoimmune diseases is driving the growth of the Benlysta market.
Benlysta Market Driver: Rising Healthcare Expenditure Drives Demand For Biologic Therapies In Lupus Treatment
Benlysta Market Segment Landscape And Growth Outlook
The benlysta market covered in this report is segmented –
1) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)
2) By Clinical Indication: Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Other Related Conditions
3) By End Users: Hospitals, Clinics, Home Care Settings, Specialty Pharmacies
Benlysta Market Industry Trends Fueling Future Revenue Growth
Leading companies in the Benlysta market are focusing on developing innovative solutions, such as autoinjectors, to improve the accessibility, adherence, and convenience of treatment for patients. Autoinjectors are devices created to deliver an exact dose of medication quickly and effortlessly, frequently allowing patients or their caregivers to administer therapy themselves at home, which reduces the need for clinic visits. For example, in May 2024, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology firm, announced that the FDA had approved its Benlysta (belimumab) autoinjector for pediatric patients aged 5 years and older suffering from systemic lupus erythematosus (SLE). This approval provides the first at-home treatment alternative for children requiring belimumab, enabling subcutaneous administration and removing the necessity for clinical visits every four weeks. The new autoinjector offers improved convenience and flexibility for caregivers, addressing the profound impact lupus has on children, including elevated rates of organ damage.
Benlysta Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the benlysta market are GlaxoSmithKline plc
View The Full Benlysta Market Report:
Benlysta Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the benlysta market in 2025. The regions covered in the benlysta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
